NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.09 -2.84 (-3.47%) GOLD FUTURES
2,308.90 +6.00 (+0.26%) DOW
37,965.07 +149.15 (+0.39%) Bitcoin GBP
46,372.41 -1,886.38 (-3.91%)
Editas Medicine, Inc. (0IFK.L)
- GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
- Insider Monkey
12 Under-the-Radar Stocks With Massive Upside for 2024
In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024. If you want to skip our overview of shareholder ownership and how shares can jump if they come ‘over’ the radar instead of under, then you can jump ahead to 5 Under-the-Radar Stocks With Massive […]
- Zacks
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
